- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Generics Recently Launched
Dr. Reddy’s launches generics of Diovan and venlafaxine ER, Apotex launches generic atropine sulfate solution, and Teva launches generic of Epiduo Forte.
Dr. Reddy’s launches generics of Diovan and venlafaxine.
Dr. Reddy’s Laboratories has launched valsartan tablets, a therapeutic equivalent generic of Novartis’ Diovan (valsartan), which is indicated to treat patients six years of age and older with hypertension.
Dr. Reddy’s valsartan is available in 40 mg in bottle count size of 30, and 80 mg, 160 mg and 320 mg tablets in bottle count sizes of 90.
Dr. Reddy’s has also launched venlafaxine ER tablets, which is used to treat depression. It is available in 150 mg and 225 mg strengths in bottle count sizes of 30 and 90.
Apotex launches generic atropine sulfate solution.
Apotex has received approval and was granted a competitive generic therapy (CGT) designation for its generic version of atropine sulfate ophthalmic solution 1%. As the first approved application, Apotex has been granted 180 days of CGT exclusivity. Atropine is indicated for the induction of cycloplegia and mydriasis, and penalization of the healthy eye in the treatment of amblyopia or “lazy eye.”
Teva launches generic of Epiduo Forte Gel.
Teva Pharmaceuticals has launched an authorized generic of Galderma’s Epiduo Forte Gel (adapalene and benzoyl peroxide) gel in the United States. Adapalene and benzoyl peroxide gel 0.3%/2.5% is a topical prescription medicine used t
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
